Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Change in Receivables (2016 - 2017)

Quarterly results put Change in Receivables at -$2000.0 for Q2 2017, down 150.0% from a year ago — trailing twelve months through Sep 2017 was -$11000.0 (up 31.25% YoY), and the annual figure for FY2020 was $467000.0, changed.

Armata Pharmaceuticals has reported Change in Receivables over the past 5 years, most recently at -$2000.0 for Q2 2017.

  • Change in Receivables reached -$2000.0 in Q2 2017 per ARMP's latest filing, up from -$10000.0 in the prior quarter.
  • Across five years, Change in Receivables topped out at $129000.0 in Q2 2013 and bottomed at -$140000.0 in Q4 2013.
  • Median Change in Receivables over the past 5 years was $4000.0 (2014), compared with a mean of -$588.24.
  • The largest annual shift saw Change in Receivables skyrocketed 152.14% in 2014 before it crashed 2600.0% in 2015.
  • Over 5 years, Change in Receivables stood at -$140000.0 in 2013, then surged by 152.14% to $73000.0 in 2014, then grew by 16.44% to $85000.0 in 2015, then plummeted by 98.82% to $1000.0 in 2016, then crashed by 300.0% to -$2000.0 in 2017.
  • Business Quant data shows Change in Receivables for ARMP at -$2000.0 in Q2 2017, -$10000.0 in Q1 2017, and $1000.0 in Q4 2016.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Change in Receivables (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - 208,524.00
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn -39.80 Mn
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn -1.20 Mn
8 Evaxion A 65.12 Bn 65.10 Bn - -
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 110.42 Mn
10 Armata Pharmaceuticals 301.92 Mn 297.17 Mn - -

Historic Data

Download Data 🔒
DateValue
Jun 30, 2017 -2,000.00
Jun 30, 2017 -2,000.00
Mar 31, 2017 -10,000.00
Mar 31, 2017 -10,000.00
Dec 31, 2016 1,000.00
Dec 31, 2016 1,000.00
Sep 30, 2016 6,000.00
Sep 30, 2016 6,000.00
Jun 30, 2016 4,000.00
Jun 30, 2016 4,000.00